Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Chemo-IO, IO-IO, or IO-mono: which is correct for lung cancer?

Benjamin Besse • 31 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses in which cases chemotherapy in combination with immunotherapy, immunotherapy alone, or a combination of immunotherapies are correct. Dr Besse believes each approach can benefit different subsets of patients. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Benjamin Besse

2:38
AZD7789 in NSCLC: safety, efficacy, and ongoing evaluation
Benjamin Besse • 24 Oct 2023
1:47
Combining ADCs with other treatment modalities in NSCLC
Benjamin Besse • 24 Oct 2023
2:50
ADC’s for the treatment of NSCLC
Benjamin Besse • 24 Oct 2023
2:28
Optimal duration of immunotherapy administration for patients with NSCLC
Benjamin Besse • 21 Oct 2023

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals